BLUESTARCO’s topline growth hinges on summer demand and EMP order revival, while bottomline resilience depends on price hike execution and cost controls; margins face structural pressure from wage codes and commodity volatility, but selective capital allocation and B2B diversification provide downside buffers.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: Average summer, EMP order book stabilizes (8–10% CAGR), price hikes partially successful (5–7% net realization).
Outcome: Revenue grows 8–10% YoY in FY27; UCP margins hold at 8.5%, EMP margins at 6.5–7%. EPS grows 5–8% YoY, supported by cost controls and selective project execution. ROCE remains 25%+. Exports contribute 5–7% of revenue by FY29, trailing the 15% target.
VOLTAS’ topline resilience hinges on RAC seasonality and Volbek scale-up, while bottomline recovery depends on commodity pass-through and project execution; margins face structural pressure unless cost optimization outpaces input inflation.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables:Normal summer demand, commodity prices stabilize, BEE price hikes absorbed (elasticity <5%), data center orders materialize.
Outcome:RAC revenue grows 3–5% YoY; market share holds at 17–18%. Voltbek break-even by Q4 FY27 (8–10% market share). Project revenue flattish but margins improve to 9–10% on MEP mix. EPS stable; margins 7–8%.
GE Vernova T&D India’s structural tailwinds (500GW renewables, TBCB adoption) and disciplined execution support 18–22% topline growth and 25–27% EBITDA, but HVDC timing, China policy, and export volatility introduce 10–15% downside risk to revenue and 100–200bps margin compression in adverse scenarios.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Adani Khavda booked in 1H FY27, Barmer-South Kalamb finalized by Q2 FY27, and TBCB pipeline supports 18–22% revenue growth. EBITDA sustains at 25–27% on execution leverage and pricing discipline. Export contributes 20–25% of revenue. Implication: In-line with guidance; cash flow funds capex.
Cipla’s topline resilience hinges on US pipeline execution (respiratory/peptides) and India chronic therapy growth, while margins face near-term pressure from R&D lumpiness and Lanreotide disruption; FY27 EBITDA recovery to 21%+ requires flawless launch sequencing and cost normalization.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Lanreotide resumes in H1 FY27; two respiratory launches in H1 FY27 (one sole generic).
Generic Victoza and one peptide launch in FY27; Yurpeak traction sustains (~₹150 crore/month).
Result:US revenue stabilizes at $130–150M/quarter; EBITDA margin recovers to 20–21%; FY27 guidance maintained at 21%.
Bajaj Auto’s Base case sees contained inflation, steady domestic growth, and KTM recovery driving 15–18% revenue with 20–21% margins. Bear case risks commodity shocks, rupee appreciation, and demand slowdown, trimming margins to 19%. Bull case highlights premiumization, EV adoption, and KTM synergies, boosting revenue 20%+.
Tata Consumer Products’ topline growth (12–16%) hinges on Sampann/RTD scaling and Tea price stability, while EBITDA margins (14–16%) depend on GTM execution and international recovery; bottom-line leverage (PAT growth) is vulnerable to commodity cycles and Starbucks’ unit economics.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: Tea prices stabilize (±5% YoY), GTM rollout completes by Q1 FY27 with 15% distributor efficiency gains, and Sampann/RTD maintain 30%/25% growth.
Outcome: Revenue grows 12–14%, with EBITDA margins expanding to 14.5–15% (scale leverage + premiumization). International margins normalize by Q2 FY27, and Starbucks delivers 4–5% SSSG. FCF remains positive (Rs. 1,000+ crore), supporting selective M&A.
Asian Paint’s Base case assumes crude at $80, flat rural demand, and stable INR, driving 6–7% revenue growth with 20–21% margins. Bear case risks higher crude, weaker demand, and rupee depreciation, cutting EPS 15–20%. Bull case sees crude easing, rural rebound, and EPS rising 18–20%.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: Crude at $80/bbl, rural demand flat, INR at 83/USD.
Outcome: Revenue grows 6-7%; EBITDA margins at 20-21%; EPS up 8-10%. Capex funded via internal accruals; leverage stable at 1.8x.
UNITEDSPR’s topline resilience in RoI and premium segments masks structural risks in Maharashtra and input cost pressures; FY26 guidance hinges on execution in pocket packs, litigation outcomes, and FTA timing, with gross margins (~47%) and EBITDA expansion (<100 bps) likely capped without favorable resolution of state-specific headwinds.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Maharashtra stabilizes with pocket pack traction and litigation progress by H2 FY26, limiting volume decline to high single-digits. FTA approved in Q1 FY27, delivering ~50 bps gross margin tailwind. A&P normalizes to 10%; premium segment growth offsets Popular weakness. Topline: +10–12%; EBITDA margin: flat to +50 bps; EPS growth: mid-teens.
Shriram Finance’s topline growth (14–16% YoY) hinges on rural/LCV demand and infra capex; bottomline (18–20% EPS growth) depends on NIM stability (8.5–8.7%) and credit cost containment (<1.7%), with execution risks skewed to MSME and customer retention strategies.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: Budget infra allocations meet expectations (HCV growth 8–10%); MSME stabilizes (Stage 3 <4.5%); funding costs drop 70–80bps.
Outcome: Disbursements grow 14–16% YoY; NIM holds at 8.5–8.7%; credit costs at 1.5–1.7%. EPS growth 18–20%, ROE ~15%.